WEST CHESTER, PA — Molecular Targeting Technologies Inc. is positioning its EvaThera platform for licensing and co-development opportunities across the radiopharmaceutical industry after Pharma Tech Outlook named the technology its 2026 Radiopharmaceutical Therapy Solution of the Year.
The clinical-stage biotechnology company is actively seeking relationships with pharmaceutical, biotechnology and radiopharmaceutical developers interested in applying EvaThera to existing and next-generation programs. Potential arrangements include licensing, co-development and integration with other companies’ radiopharmaceutical pipelines.
EvaThera uses Evans Blue-mediated reversible albumin binding to alter how targeted radiopharmaceuticals circulate and remain in tumors. Rather than requiring development of a new molecular target, the platform is designed to work with established and investigational targeting ligands to potentially extend circulation, increase tumor exposure and prolong tumor retention.
That approach gives MTTI a potential business opportunity beyond its own drug pipeline. The company is developing EvaThera as a modular platform capable of working across multiple molecular targets and therapeutic radionuclides.
“EvaThera offers pharmaceutical and radiopharmaceutical developers a new opportunity to optimize the pharmacokinetic performance of existing or investigational targeting strategies,” Chief Strategy Officer Norman LaFrance said. He said the approach could create opportunities for “strategic collaborations, licensing, and co-development” with other companies.
The first clinical application supporting the platform is Lu-EBTATE, an albumin-binding radiopharmaceutical targeting somatostatin receptor 2, or SSTR2, for gastroenteropancreatic neuroendocrine tumors. MTTI said the candidate is being advanced toward pivotal Phase III clinical development.
Clinical experience with Lu-EBTATE in 81 patients showed tumor retention for as long as 15 days, according to MTTI. Comparative clinical analyses showed as much as approximately eightfold higher tumor uptake and/or retention compared with Lu-DOTA-TATE, while preclinical studies showed as much as 35-fold greater uptake and retention in certain models.
MTTI also said the evaluated two-cycle Lu-EBTATE regimen used approximately 12.5% of the cumulative administered radioactivity of a conventional four-cycle Lutathera regimen. The company cautioned that the comparison concerns administered activity and is not a direct measure of whole-body or organ radiation exposure.
Beyond SSTR2, MTTI is developing EvaThera programs involving integrin αvβ3, fibroblast activation protein, or FAP, and gastrin-releasing peptide receptor, or GRPR. The platform is also being developed for use with lutetium-177 and actinium-225.
MTTI Chairman and CEO Chris Pak said the company’s strategy is based on improving how therapeutic radiation is delivered rather than relying solely on the discovery of new molecular targets.
“By enhancing tumor exposure and retention, we believe pharmacokinetic engineering has the potential to complement molecular targeting and help advance the therapeutic index of targeted radiopharmaceuticals,” Pak said.
Additional information about MTTI and EvaThera is available at www.mtarget.com and www.evathera.com, while the Pharma Tech Outlook feature is available at https://www.pharmatechoutlook.com/molecular-targeting-technologies-inc-2026.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.